NNZ-2591 is an investigational therapeutic compound being developed for the treatment of neurodevelopmental and neurological disorders. It has shown promise in preclinical and clinical studies for conditions such as traumatic brain injury, stroke, neurodegenerative diseases, and rare genetic disorders affecting the nervous system, including Phelan-McDermid syndrome. The compound is believed to work by modulating neuroinflammatory pathways, promoting neuroprotection, restoring neuronal function, reducing inflammation, and potentially supporting neurogenesis. Research is ongoing to evaluate its efficacy and safety in clinical trials, with the aim of establishing it as a treatment option for these challenging conditions.